TAmiRNA Senior Scientist Teresa Lara Krammer will attend MEDICA Düsseldorf next week to speak about “thrombomiRs - circulating microRNAs as novel platelet activation markers?”. Reach out to Teresa directly to meet with her before or after her presentation on Tuesday, Nov. 14th at 14:50, Halle1/G37 and discuss our latest developments and how TAmiRNA’s products and services can assist your business!
TAmiRNA Scientific Consultant Magdalena Mecking is attending the Extracellular Vesicles Forum on Oct 10th – 11th in Cambridge. Stop by one of her posters and learn more about how TAmiRNA’s service may benefit your EV project! Reach out to Magdalena directly and discuss our latest developments and how TAmiRNA's services can assist your business!
Today we announce that TAmiRNA has received ISO 13485:2016 certification for its Medical Device and Quality Management System after successfully completing the audit through Germany-based notified body MDC. This ISO certification indicates that TAmiRNAs quality management system meets the most current regulatory requirements applicable to the medical device industry. "We are very proud of this certification as it demonstrates the commitment of our team to meet customer and international regulatory expectations," said Matthias Hackl, Co-Founder and CEO of TAmiRNA. ISO 13485:2016 is an internationally recognized quality systems standard tailored to the development and manufacturing of medical devices, including in-vitro diagnostic tests. This certification represents an important milestone for our company, and reflects our rigorous and risk-based approach [...]
We want to draw your attention to our most recent publication where we investigated platelet-enriched miRNAs (thrombomiRs) as suitable candidates for monitoring antiplatelet therapy. The study provides evidence that thrombomiRs are promising biomarker candidates for monitoring the extent of platelet inhibition. This could enable stratification of patients depending on their response to antiplatelet therapy and guide treatment decisions. click here to read the paper
The collaboration between Biogenity and TAmiRNA is a big step towards further enabling our clients to identify new biomarkers that can be used to diagnose disease, monitor treatment response, and predict patient outcomes. And an important step to advance omics research and bring better healthcare to future generations. click here to read the press release
TAmiRNA has launched an innovative NGS technology for absolute quantitation of miRNAs and other small RNAs , the miND® (microRNA Next-Generation Sequencing Discovery) spike-in. The miND® spike-in has been developed for small RNA sequencing experiments and absolute quantitation of microRNAs in any biological matrix and species, overcoming previous challenges of quality control and difficulty in achieving absolute quantitation of miRNAs across different biological matrix and species. click here for more Information on the miND spike-ins
